VTX2735的开放标签试验研究在复发性心包炎中
一项2A阶段的开放标签试验研究,用于评估VTX2735的安全性/耐受性,功效,药代动力学和药效学的参与者,
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).
Cohort A will include approximately 10 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A
- A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A
- An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Cohort B will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C
- A 14-day Follow-Up Period
Cohort C will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Ventyx Clinical Trial Contact
- 电话号码:ext 108 888-411-5176
- 邮箱:ClinicalTrials@ventyxbio.com
学习地点
-
-
-
Montreal、加拿大、H4A 3J1
- 尚未招聘
- Local Site #840102
-
Ottawa、加拿大、K1Y 4S7
- 招聘中
- Local Site #840101
-
-
-
-
-
Athens、希腊、11527
- 尚未招聘
- Local Site #300001
-
-
-
-
-
Ghent、比利时、9000
- 招聘中
- Local Site #056001
-
Leuven、比利时、3000
- 招聘中
- Local Site #056002
-
-
-
-
California
-
La Jolla、California、美国、92037
- 招聘中
- Site Location #840023
-
Orange、California、美国、92868
- 招聘中
- Local Site #840014
-
-
Florida
-
Saint Augustine、Florida、美国、32086
- 招聘中
- Local Site #840016
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Local Site #840008
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Local Site #840010
-
-
Minnesota
-
Rochester、Minnesota、美国、55905-0002
- 招聘中
- Local Site #840005
-
首席研究员:
- Sushil Luis
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Local Site #840020
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Local Site #840017
-
-
Texas
-
Houston、Texas、美国、77034
- 招聘中
- Local Site #840001
-
Houston、Texas、美国、77030
- 招聘中
- Local Site #840019
-
首席研究员:
- Maan Malahfji
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- 招聘中
- Local Site #840013
-
-
Vermont
-
Burlington、Vermont、美国、05401
- 招聘中
- Local Site #840022
-
-
Virginia
-
Richmond、Virginia、美国、23298
- 招聘中
- Local Site #840004
-
Richmond、Virginia、美国、23298
- 招聘中
- Local Site #840018
-
-
Washington
-
Seattle、Washington、美国、98105
- 招聘中
- Local Site #840021
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 75 years of age.
- Capable of giving signed informed consent and able to comply with the protocol
- Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
- Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
- CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
- Pericarditis pain score ≥ 4 based on the 11-point NRS.
- Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
Exclusion Criteria:
- Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
- History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
- Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:队列A
|
Dose A, Daily
其他名称:
Dose B, Daily
其他名称:
Dose C, Daily
其他名称:
Dose D, Daily
其他名称:
Dose E, Daily
其他名称:
|
|
实验性的:B 组 治疗组 B1
|
Dose A, Daily
其他名称:
Dose B, Daily
其他名称:
Dose C, Daily
其他名称:
Dose D, Daily
其他名称:
Dose E, Daily
其他名称:
|
|
实验性的:B 组 治疗组 B2
|
Dose A, Daily
其他名称:
Dose B, Daily
其他名称:
Dose C, Daily
其他名称:
Dose D, Daily
其他名称:
Dose E, Daily
其他名称:
|
|
实验性的:Cohort C Treatment Group C1
|
Dose A, Daily
其他名称:
Dose B, Daily
其他名称:
Dose C, Daily
其他名称:
Dose D, Daily
其他名称:
Dose E, Daily
其他名称:
|
|
实验性的:Cohort C Treatment Group C2
|
Dose A, Daily
其他名称:
Dose B, Daily
其他名称:
Dose C, Daily
其他名称:
Dose D, Daily
其他名称:
Dose E, Daily
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of VTX2735
大体时间:Day 1 of treatment period through study completion, up to 26 weeks
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation |
Day 1 of treatment period through study completion, up to 26 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Effect of VTX2735 on pericardial pain
大体时间:Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in Numeric Pain Rating Scale (NRS) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
|
Effect of VTX2735 on inflammation
大体时间:Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.